ACADIA Pharmaceuticals Inc Corporate Call - Regulatory Update on Supplemental New Drug Application Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Just as we look where you go from here, just if you could perhaps speak to how you're going to organize around this issue. What are those next steps? How you plan to update and provide disclosures to us and the street around getting some of the detail on the FDA. And then just related to that, certainly on the organization to run, the commercial leadership change and certainly patients and folks lying in wait waiting in the wings here, how you think about those impacts when you talk about allocating resources certainly going forward for the rest of the -- for the remainder of the year.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : We know that patients in the HARMONY trial had no worsening in cognition or motor function. There were no specific questions from the FDA on HARMONY so far, and you said you're confident about quality and extent of data. But do you think the time frame of the HARMONY trial, that's the 12 plus 26 weeks, provides enough info on the risk/benefit profile of pimavanserin specifically to gauge an impact on cognition in this older patient set?